Biotech Values

[iwfal]

Thus, 5 or 6 of the 86 patients in question had a viral breakthrough while on the SoC portion of the regimen.

And another point is that 28 out of 53 treatment completers relapsed in the no-ribavirin arm, whereas 2 out of 53 treatment completers relapsed in the exactly equivalent arm with ribavirin. SoC (IFN plus ribavirin for 24 weeks) really knocks down the relapse rate after cessation of treatment if you can just get by the AE induced dropout rate for SoC.

Reminder (to understand the context of my questions):

The thesis I am interested in is whether IFN is likely to have a place in the HCV universe after anti-virals become SoC. I have previous supposed that there was a good chance of a very high relapse rate if an immune modulator does not follow direct anti-virals. With this data I would now state that thesis with more confidence - making it a predict.